Drug Profile


Alternative Names: Anti-PDL-1-Genentech/Roche; MPDL-3280A; RG-7446; RO 5541267; TECENTRIQ

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer ARCAGY/GINECO Group; Astex Pharmaceuticals; Chugai Pharmaceutical; Clovis Oncology; Columbia University; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer; Exelixis; Fondazione Michelangelo; Genentech; Immune Design; Incyte Corporation; M. D. Anderson Cancer Center; National Cancer Institute (USA); Roche; University Medical Center Groningen; University of California at San Francisco; University of California System; Yale University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Urogenital cancer
  • Preregistration Bladder cancer
  • Phase III Breast cancer; Colorectal cancer; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Chronic lymphocytic leukaemia; Soft tissue sarcoma; Solid tumours
  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I Acute myeloid leukaemia; Gynaecological cancer; Multiple myeloma; Myelodysplastic syndromes
  • No development reported Haematological malignancies

Most Recent Events

  • 22 Jun 2017 Roche plans a phase III trial for Non-small cell lung cancer(Treatment naive, Metastatic disease, Late-stage) in Argentina, Belgium, Brazil, Canada, Denmark, India, Luxembourg, Portugal, Switzerland and United Kingdom (NCT03191786)
  • 13 Jun 2017 Roche plans a phase II/III trial for Non-small cell lung cancer(Monotherapy, Combination therapy, Inoperable/unresectable, Metastatic disease, Late-stage disease) in USA, Australia, Belgium, Brazil, Canada, France, Hong Kong, Italy, South Korea, Mexico, Poland, Spain and Thailand (NCT03178552)
  • 12 Jun 2017 Phase-I clinical trials in Renal cell carcinoma (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top